Cargando…
2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model
BACKGROUND: Fluconazole is lifesaving for the treatment and prevention of cryptococcosis; however, optimal dosing is unknown. Initial fluconazole doses of 100 mg to 2000 mg/day have been used. Prevalence of fluconazole non-susceptible Cryptococcus is increasing over time, risking the efficacy of lon...
Autores principales: | Chesdachai, Supavit, Rajasingham, Radha, Nicol, Melanie R, Meya, David, Bongomin, Felix, Abassi, Mahsa, Skipper, Caleb, Kwizera, Richard, Rhein, Joshua, Boulware, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809647/ http://dx.doi.org/10.1093/ofid/ofz360.1800 |
Ejemplares similares
-
Minimum Inhibitory Concentration Distribution of Fluconazole Against Cryptococcus Species and the Fluconazole Exposure Prediction Model
por: Chesdachai, Supavit, et al.
Publicado: (2019) -
Emerging fluconazole resistance: Implications for the management of cryptococcal meningitis
por: Mpoza, Edward, et al.
Publicado: (2017) -
ATI-2307 Exhibits Equivalent Antifungal Activity in Cryptococcus neoformans Clinical Isolates With High and Low Fluconazole IC(50)
por: Gerlach, Elliot S., et al.
Publicado: (2021) -
Baseline Serum C-Reactive Protein Level Predicts Mortality in Cryptococcal Meningitis
por: Chesdachai, Supavit, et al.
Publicado: (2020) -
1716. Baseline Serum C-Reactive Protein Level Predicts Mortality in Cryptococcal Meningitis
por: Chesdachai, Supavit, et al.
Publicado: (2019)